CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion st

CAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cull

Cullinan Therapeutics remains a compelling buy as zipalertinib approaches a key FDA decision for EGF

Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in

CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and

New and updated clinical data to be presented from over 30 patients across systemic lupus erythemato

Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to ad

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc.  (Nasdaq: CGEM), a cl

MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discov

Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR

Cullinan Therapeutics's Zipalertinib NDA has been accepted, making its February 27, 2027, PDUFA date

PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceuti

Genprex (NASDAQ: GNPX - Get Free Report) and Cullinan Therapeutics (NASDAQ: CGEM - Get Free Report)

Cullinan Therapeutics (NASDAQ: CGEM) outlined a milestone-heavy roadmap during a presentation at Lee

Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA conf

Cullinan Therapeutics (NASDAQ: CGEM) executives highlighted upcoming clinical milestones for the com

Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) CEO Nadim Ahmed sold 16,381 shares of t

Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) insider Jennifer Michaelson sold 11,742

CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cull